Compare
Jazz Pharmaceuticals vs Lilly (Eli) (JAZZ vs LLY)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Jazz Pharmaceuticals (JAZZ) returned +71.1% and Lilly (Eli) (LLY) +46.2%; so far this year the figures are +38.1% and +26.0%.
Lilly (Eli) is the larger company by market value, about 84.5 times the size of Jazz Pharmaceuticals.
On trailing earnings, JAZZ trades at 76.5 times and LLY at 43.9 times.
Revenue grew +13.5% at JAZZ and +45.5% at LLY over the last year.
JAZZ pays no dividend. LLY yields 0.49%.
Data as of the latest close. Not investment advice.
Relative performance
| JAZZ | LLY | |
|---|---|---|
| Price | $234.76 | $1,354.00 |
| 1-day | +3.27% | -0.79% |
| YTD | +38.09% | +25.99% |
| 1 year | +71.08% | +46.25% |
| 3 years | +84.36% | +144.20% |
| Market cap | $15.1B | $1.27T |
| P/E | 76.5 | 43.9 |
| P/S | 3.19 | 14.73 |
| P/B | 3.59 | 31.63 |
| Revenue growth | +13.50% | +45.50% |
| EPS growth | — | +50.70% |
| Gross margin % | — | 83.6 |
| Net margin % | 4.4 | 31.9 |
| ROE % | 4.9 | 68.5 |
| Debt / equity | 1.33 | 1.23 |
| FCF yield % | 10.8 | 2.4 |
| Dividend yield % | — | 0.49 |
| Beta | 0.53 | 0.29 |
| RSI (14) | 60.5 | 61.1 |
| Technical rating |